| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2137649 | Leukemia Research | 2011 | 5 Pages |
Abstract
Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3 g/m2 over 3 h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9 mg/m2 on day 7 and 4.5 mg/m2 on day 14 was not tolerated, but HiDAC followed by GO 9 mg/m2 on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Richard M. Stone, Barry Moser, Ben Sanford, Philip Schulman, Jonathan E. Kolitz, Steven Allen, Wendy Stock, Ilene Galinsky, Ravi Vij, Guido Marcucci, David Hurd, Richard A. Larson,